The National Institutes of Health has announced the first clinical trial of a vaccine to protect healthy people from infection by the Ebola virus, which is responsible for an estimated 1,550 deaths throughout West Africa.
The passage of the Humane Cosmetics Act and the insertion of a similar "last resort" clause into the House and Senate TSCA reform bills could save countless lives — both human and animal. We can do better than rely on animals to predict human results. It's time to let go of the methods of the past and embrace 21st-century science.
The city of Laurel is hosting a series of movies and concerts on Fridays during the summer at Granville Gude Park, 8300 Mulberry St. Attendees are encouraged to bring a comfortable chair or blanket. All events are family friendly.
Human Genome Sciences Inc., which was acquired for $3.6 billion by London-based GlaxoSmithKline Plc in August, intends to lay off 97 employees in mid-December, and an additional but unspecified number of cuts are planned for next year, the company warned Maryland labor regulators this week.
Human Genome, which uses the human DNA sequence to develop targeted drugs, was able to raise its price to $14.25 for sale to London-based GlaxoSmithKline Plc, valuing the company at $3.6 billion. In April, GlaxoSmithKline offered to buy Human Genome for $13 a share, or $2.6 billion.
Human Genome ultimately rebuffed a $2.6 billion offer by biopharmaceutical giant GlaxoSmithKline Plc, saying it was too low – though it has put itself on the market. Catalyst agreed to be acquired by a larger Illinois competitor for $4.4 billion.
Shares of Human Genome Sciences doubled in Thursday morning trading on news it received a $2.6 billion cash offer to acquire the company from a major bio pharmaceutical company, which it rejected as too low.